PathoQuest highlighted the growing adoption of next generation sequencing (NGS) in Asia-Pacific biologics development, supporting viral safety, contamination detection, and regulatory alignment during the APAC Biomanufacturing Leadership Summit 2026.

• Technology: NGS enables sensitive detection of viral contaminants and adventitious agents, complementing traditional testing methods in biologics and advanced therapies.
• Adoption: Increasing regulatory interest in integrating NGS into development workflows, with emphasis on validation, reproducibility, and compliance with quality systems.
• Impact: Supports earlier contamination detection and improved process understanding, strengthening product safety and regulatory confidence in complex biomanufacturing.

This summary is based on a news article by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.